vs

Side-by-side financial comparison of Health Catalyst, Inc. (HCAT) and LINCOLN EDUCATIONAL SERVICES CORP (LINC). Click either name above to swap in a different company.

LINCOLN EDUCATIONAL SERVICES CORP is the larger business by last-quarter revenue ($142.9M vs $74.7M, roughly 1.9× Health Catalyst, Inc.). LINCOLN EDUCATIONAL SERVICES CORP runs the higher net margin — 8.9% vs -121.9%, a 130.8% gap on every dollar of revenue. On growth, LINCOLN EDUCATIONAL SERVICES CORP posted the faster year-over-year revenue change (19.7% vs -6.2%). LINCOLN EDUCATIONAL SERVICES CORP produced more free cash flow last quarter ($25.0M vs $9.6M). Over the past eight quarters, LINCOLN EDUCATIONAL SERVICES CORP's revenue compounded faster (17.6% CAGR vs -0.0%).

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

Lincoln Tech is an American group of for-profit postsecondary vocational institutions headquartered in Parsippany, New Jersey with campuses in Colorado, Connecticut, Georgia, Illinois, Indiana, Maryland, New Jersey, New York, Pennsylvania, Rhode Island, Tennessee, and Texas. Each campus is owned and operated by Lincoln Educational Services Corporation, a provider of career-oriented post-secondary education.

HCAT vs LINC — Head-to-Head

Bigger by revenue
LINC
LINC
1.9× larger
LINC
$142.9M
$74.7M
HCAT
Growing faster (revenue YoY)
LINC
LINC
+25.9% gap
LINC
19.7%
-6.2%
HCAT
Higher net margin
LINC
LINC
130.8% more per $
LINC
8.9%
-121.9%
HCAT
More free cash flow
LINC
LINC
$15.4M more FCF
LINC
$25.0M
$9.6M
HCAT
Faster 2-yr revenue CAGR
LINC
LINC
Annualised
LINC
17.6%
-0.0%
HCAT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
HCAT
HCAT
LINC
LINC
Revenue
$74.7M
$142.9M
Net Profit
$-91.0M
$12.7M
Gross Margin
62.3%
Operating Margin
-115.3%
12.4%
Net Margin
-121.9%
8.9%
Revenue YoY
-6.2%
19.7%
Net Profit YoY
-340.3%
85.9%
EPS (diluted)
$-1.29
$0.41

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HCAT
HCAT
LINC
LINC
Q4 25
$74.7M
$142.9M
Q3 25
$76.3M
$141.4M
Q2 25
$80.7M
$116.5M
Q1 25
$79.4M
$117.5M
Q4 24
$79.6M
$119.4M
Q3 24
$76.4M
$114.4M
Q2 24
$75.9M
$102.9M
Q1 24
$74.7M
$103.4M
Net Profit
HCAT
HCAT
LINC
LINC
Q4 25
$-91.0M
$12.7M
Q3 25
$-22.2M
$3.8M
Q2 25
$-41.0M
$1.6M
Q1 25
$-23.7M
$1.9M
Q4 24
$-20.7M
$6.8M
Q3 24
$-14.7M
$4.0M
Q2 24
$-13.5M
$-682.0K
Q1 24
$-20.6M
$-214.0K
Gross Margin
HCAT
HCAT
LINC
LINC
Q4 25
62.3%
Q3 25
52.6%
59.5%
Q2 25
59.8%
Q1 25
59.7%
Q4 24
62.2%
Q3 24
47.5%
58.0%
Q2 24
55.7%
Q1 24
58.4%
Operating Margin
HCAT
HCAT
LINC
LINC
Q4 25
-115.3%
12.4%
Q3 25
-22.9%
4.4%
Q2 25
-46.0%
2.5%
Q1 25
-25.4%
2.9%
Q4 24
-22.0%
9.2%
Q3 24
-17.9%
5.1%
Q2 24
-20.8%
-1.1%
Q1 24
-30.5%
-0.4%
Net Margin
HCAT
HCAT
LINC
LINC
Q4 25
-121.9%
8.9%
Q3 25
-29.1%
2.7%
Q2 25
-50.8%
1.3%
Q1 25
-29.9%
1.7%
Q4 24
-26.0%
5.7%
Q3 24
-19.3%
3.5%
Q2 24
-17.8%
-0.7%
Q1 24
-27.6%
-0.2%
EPS (diluted)
HCAT
HCAT
LINC
LINC
Q4 25
$-1.29
$0.41
Q3 25
$-0.32
$0.12
Q2 25
$-0.59
$0.05
Q1 25
$-0.35
$0.06
Q4 24
$-0.33
$0.22
Q3 24
$-0.24
$0.13
Q2 24
$-0.23
$-0.02
Q1 24
$-0.35
$-0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HCAT
HCAT
LINC
LINC
Cash + ST InvestmentsLiquidity on hand
$95.7M
$28.5M
Total DebtLower is stronger
$153.3M
Stockholders' EquityBook value
$245.8M
$199.7M
Total Assets
$502.6M
$493.2M
Debt / EquityLower = less leverage
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HCAT
HCAT
LINC
LINC
Q4 25
$95.7M
$28.5M
Q3 25
$91.5M
$13.5M
Q2 25
$97.3M
$16.7M
Q1 25
$342.0M
$28.7M
Q4 24
$392.0M
$59.3M
Q3 24
$387.3M
$54.0M
Q2 24
$308.3M
$67.0M
Q1 24
$327.8M
$68.6M
Total Debt
HCAT
HCAT
LINC
LINC
Q4 25
$153.3M
Q3 25
$153.1M
Q2 25
$153.0M
Q1 25
$382.9M
Q4 24
$382.4M
Q3 24
$345.0M
Q2 24
Q1 24
Stockholders' Equity
HCAT
HCAT
LINC
LINC
Q4 25
$245.8M
$199.7M
Q3 25
$331.9M
$185.9M
Q2 25
$347.5M
$180.7M
Q1 25
$376.8M
$177.8M
Q4 24
$365.2M
$178.3M
Q3 24
$355.0M
$170.0M
Q2 24
$357.0M
$164.9M
Q1 24
$357.2M
$164.5M
Total Assets
HCAT
HCAT
LINC
LINC
Q4 25
$502.6M
$493.2M
Q3 25
$587.1M
$466.9M
Q2 25
$616.2M
$447.3M
Q1 25
$891.5M
$427.4M
Q4 24
$858.9M
$436.6M
Q3 24
$813.0M
$404.0M
Q2 24
$691.7M
$366.4M
Q1 24
$695.1M
$355.2M
Debt / Equity
HCAT
HCAT
LINC
LINC
Q4 25
0.62×
Q3 25
0.46×
Q2 25
0.44×
Q1 25
1.02×
Q4 24
1.05×
Q3 24
0.97×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HCAT
HCAT
LINC
LINC
Operating Cash FlowLast quarter
$9.9M
$43.5M
Free Cash FlowOCF − Capex
$9.6M
$25.0M
FCF MarginFCF / Revenue
12.9%
17.5%
Capex IntensityCapex / Revenue
0.4%
13.0%
Cash ConversionOCF / Net Profit
3.43×
TTM Free Cash FlowTrailing 4 quarters
$-697.0K
$-27.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HCAT
HCAT
LINC
LINC
Q4 25
$9.9M
$43.5M
Q3 25
$-464.0K
$23.9M
Q2 25
$-9.0M
$299.0K
Q1 25
$280.0K
$-8.4M
Q4 24
$-3.5M
$30.3M
Q3 24
$6.2M
$5.6M
Q2 24
$1.6M
$8.3M
Q1 24
$10.3M
$-14.9M
Free Cash Flow
HCAT
HCAT
LINC
LINC
Q4 25
$9.6M
$25.0M
Q3 25
$-719.0K
$2.0M
Q2 25
$-9.2M
$-26.1M
Q1 25
$-390.0K
$-28.3M
Q4 24
$-3.9M
$5.5M
Q3 24
$5.5M
$-13.8M
Q2 24
$1.3M
$-2.7M
Q1 24
$10.1M
$-16.6M
FCF Margin
HCAT
HCAT
LINC
LINC
Q4 25
12.9%
17.5%
Q3 25
-0.9%
1.4%
Q2 25
-11.4%
-22.4%
Q1 25
-0.5%
-24.1%
Q4 24
-4.9%
4.6%
Q3 24
7.2%
-12.0%
Q2 24
1.7%
-2.6%
Q1 24
13.5%
-16.1%
Capex Intensity
HCAT
HCAT
LINC
LINC
Q4 25
0.4%
13.0%
Q3 25
0.3%
15.5%
Q2 25
0.3%
22.7%
Q1 25
0.8%
16.9%
Q4 24
0.5%
20.8%
Q3 24
0.9%
16.9%
Q2 24
0.4%
10.7%
Q1 24
0.3%
1.6%
Cash Conversion
HCAT
HCAT
LINC
LINC
Q4 25
3.43×
Q3 25
6.29×
Q2 25
0.19×
Q1 25
-4.31×
Q4 24
4.43×
Q3 24
1.42×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

LINC
LINC

Transferred Over Time$136.0M95%
Transferred At Point In Time$6.9M5%

Related Comparisons